(SILO) Reaches $2.33 On Big Swing Marking An Approx. 111% Overnight Move

*Sponsored Krypton Street Announces Coverage On Silo Pharma, Inc. (Nasdaq: SILO) Starting This Morning—Wednesday, May 14, 2025 And Here’s Why… Low Float With Fewer Than 5M Shares Could Set The Stage For Significant Swing Potential If Demand Begins To Shift. (SILO) Just Moved Approximately 51% In One Week, Climbing From $0.74 On May 5 To $1.12 Earlier Yesterday, May 13, Trending Above Several Key Averages. (SILO) Moved From $0.841 To $4.50 In Under Two Weeks—An Approximate 435% Move In July 2024, That Still Stands Out On The Chart. With Its Market Cap Below $5M, (SILO) Appears To Be Flying Under The Radar—Until Now. Pull Up (SILO) Before The Bell Rings… May 14, 2025 Dear Reader, The spotlight is on (SILO) this morning. (SILO) reached $2.33 in the early session—marking an approximate 111% overnight move from yesterday's $1.10 close. This is what I was talking about with these low float biotechs.  Take a look at this before the bell rings. Every so often, a little-known company operating under the radar steps into focus—fueled not by speculation, but by science. That’s exactly what’s happening with Silo Pharma, Inc. (Nasdaq: SILO)—a developmental-stage biopharmaceutical company that’s quietly assembling the kind of pipeline, licensing power, and institutional partnerships that have begun to attract fresh attention across the CNS therapeutic landscape. And the spotlight is now getting brighter. (SILO) just moved approximately 51% in about a week— from $0.74 on May 5 to $1.12 earlier yesterday, May 13.  With a float under 5M shares and a market cap still below $5M , this is the kind of setup that doesn’t go unnoticed for long.  It's now trending above both its 5- and 20-day moving averages, while its 50- and 100-day averages—sitting around $1.1178 and $1.2775—may come into view sooner than many realize. Could this be the beginning of something much bigger?  When you look back at (SILO)’s chart, you’ll see that it made an approximate 435% move in less than two weeks last summer—climbing from $0.841 on July 9 to $4.50 by July 18, 2024. That kind of historic breakout potential doesn’t guarantee a repeat—but it does make this technical setup all the more exciting to watch. We have all eyes on (SILO) this morning heading into the open. Beyond the Chart: What’s Driving the Story… While the recent move has brought fresh attention to the name, what’s unfolding inside the company is even more compelling. (SILO) isn’t chasing trends.  It’s targeting long-ignored neurological and mental health conditions with innovative delivery systems and exclusive rights that could potentially change how patients with PTSD, fibromyalgia, Alzheimer’s disease, and multiple sclerosis are treated. And now—with human trials on the near horizon, new patents in hand, and key preclinical milestones achieved—this company has entered a critical phase. What’s Fueling the Attention Around Silo Pharma? There’s more than one reason (SILO) is starting to stand out on both scientific and technical radars.  Here are some of the key developments that have positioned the company for increasing visibility in 2025: Silo’s lead program, SPC-15, is advancing through final GLP-compliant studies and could soon enter first-in-human trials.  This patented intranasal compound is designed to deliver targeted effects for PTSD and anxiety by bypassing the blood-brain barrier using nose-to-brain delivery. Both SPC-15 and Alzheimer’s-focused SPC-14 are exclusively licensed from Columbia University, giving (SILO) global rights to develop, manufacture, and commercialize two high-potential compounds in the CNS space. The company has aligned with the FDA to pursue the streamlined 505(b)(2) regulatory pathway—a strategy that may accelerate development timelines and reduce costs for both SPC-15 and SP-26, a chronic pain implant designed for at-home, extended-release ket-a-mine therapy. On the intellectual property front, (SILO) has moved quickly.  In just the first quarter of 2025, it announced multiple patent grants and new filings—strengthening its protection around SPC-15 and opening the door to future combination therapies in stress-related disorders. Behind the Scenes: A Shift in Tone from the Top… In a recent shareholder letter, CEO Eric Weisblum shared a more candid view of the road ahead. He emphasized not just the milestones achieved, but the capital discipline (SILO) has maintained—operating debt-free, advancing through development phases without overextension, and expanding only when supported by scientific and regulatory progress. Meanwhile, Dr. James Kuo, a veteran of multiple listed bioscience companies, has taken the helm of Silo’s research and development efforts.  His leadership, alongside a deep bench of advisory board members—including renowned psychiatrist Dr. Charles Nemeroff—signals the company’s intention to build more than a pipeline.  It’s building credibility. Recent Developments Silo Pharma (NASDAQ: SILO) has entered a key execution phase in 2025, delivering three notable updates in just a few weeks—each strengthening its clinical trajectory and position in CNS-focused research. April 30, 2025 – SP-26 Hits All Endpoints (SILO)’s extended-release ket-a-mine implant, SP-26, met all preclinical study goals in fibromyalgia, showing strong tolerability, no implant-related issues, and 22-day sustained plasma levels—supporting its path forward as a potential at-home, long-acting treatment for chronic pain. April 28, 2025 – SPC-14 Patent Filed (SILO) filed a U.S. patent for SPC-14, its Alzheimer’s candidate licensed from Columbia University, featuring a dual-receptor mechanism targeting cognitive and neuropsychiatric symptoms—strengthening both the scientific case and its IP position. March 26, 2025 – SPC-15 Advances Toward IND (SILO) began dosing in its final GLP study for SPC-15, an intranasal PTSD therapy, following FDA alignment on the 505(b)(2) pathway—marking the last step before first-in-human trials. FDA. Pipeline. Chart. All Pointing One Way… With years of research already behind it, (SILO) is no longer just a concept-stage biotech. The timeline to clinical trials is now clear. Following FDA guidance and successful pre-IND developments, SPC-15 may soon transition from lab studies to real-world human use cases. At the same time, the company’s expansion into Alzheimer’s disease and MS research through candidates SPC-14 and SPU-16 demonstrates a broader ambition to make measurable impacts across multiple neurological frontiers—many of which have seen little innovation for decades. This next phase, if executed well, could be where everything changes. As momentum builds, technicals shift, and the company checks off meaningful milestones—there’s a growing sense that (SILO) may no longer stay under the radar. The chart has history.  The pipeline has depth.  And the timing? That’s what makes this one worth watching. Here’s what we’re seeing right now—fact by fact—that has our full focus going into the morning. 7 Reasons Why We Have All Eyes On (SILO) This Morning… 1. Low Float: With fewer than 5M shares outstanding, (SILO) sits in a held range that has historically amplified swing potential when momentum builds. 2. Recent Market Recognition: (SILO) climbed approximately 51% in one week—from $0.74 on May 5 to $1.12 early yesterday, on May 13—while trending above both its 5- and 20-day moving averages. 3. Breakout History Exists: Back in July 2024, (SILO) moved from $0.841 to $4.50 in under two weeks, marking an approximate 435% move that still draws attention when looking at the chart. 4. Trial Timeline Advancing: (SILO)’s lead program SPC-15 is in final IND-enabling studies, following FDA alignment for a streamlined clinical path using the 505(b)(2) route. 5. Patent Coverage Expanding: In Q1 and Q2 of 2025, (SILO) filed new patent protections for SPC-15 and SPC-14—reinforcing its rights across PTSD and Alzheimer’s programs. 6. Leadership Stands Out: With a team that includes biotech veteran Dr. James Kuo and advisor Dr. Charles Nemeroff, (SILO) has aligned itself with recognized CNS expertise. 7. Under The Radar: Despite clinical progress, new filings, and licensing from Columbia University, (SILO) continues to hold a market cap below $5M as of today. The timing feels intentional.  And the pieces—technical, structural, and clinical—are lining up in a way we don’t see often. Each of these factors alone might not turn heads—but together, they form a story that deserves a closer look. Momentum has already started to build, and if history is any guide, the next chapter could move fast. Take A Look At (SILO) Before The Bell Rings… As clinical progress accelerates and technical signals begin to align, Silo Pharma (NASDAQ: SILO) continues to stand out for reasons both structural and scientific.  From its under-the-radar valuation to its tightening float and regulatory momentum, this is a name that has quietly built the foundation for broader recognition. We have all eyes on (SILO) this morning. Take a look at (SILO) before the bell rings. (SILO) reached $2.33 in the early session—marking an approximate 111% overnight move from yesterday's $1.10 close.  Make sure you keep an eye out for my next update—it could be coming at any moment. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 05/13/2025 and ending on 05/14/2025 to publicly disseminate information about (SILO:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (SILO:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/silo-9f6mx/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice